Transforming berberine into its intestine-absorbable form by the gut microbiota

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Feng, Ru ^a   Shou, Jia Wen ^a   Zhao, Zhen Xiong ^a   He, Chi Yu ^a   Ma, Chao ^b   Huang, Min ^a   Fu, Jie ^a   Tan, Xiang Shan ^a   Li, Xiao Yang ^a   Wen, Bao Ying ^a   Chen, Xi ^a   Yang, Xin Yi ^c   Ren, Gang ^c   Lin, Yuan ^a   Chen, Yangchao ^d   You, Xue Fu ^c   Wang, Yan ^a   Jiang, Jian Dong ^a,c  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b Shimadzu International Trading Co Ltd   (China)

^c INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^d Prince of Wales Hospital   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BACTERIAL PROTEIN; BERBERINE; DIHYDROBERBERINE; NITROREDUCTASE;

ANALOGS AND DERIVATIVES; ANIMAL; BACTERIUM; BINDING SITE; CHEMISTRY; ENZYMOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE; INTESTINE ABSORPTION; INTESTINE FLORA; ISOLATION AND PURIFICATION; MALE; METABOLISM; MICROBIOLOGY; MOLECULAR DOCKING; MOUSE; ORAL DRUG ADMINISTRATION; OXIDATION REDUCTION REACTION; SOLUBILITY; SPRAGUE DAWLEY RAT; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ANIMALS; BACTERIA; BACTERIAL PROTEINS; BERBERINE; BINDING SITES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GASTROINTESTINAL MICROBIOME; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; INTESTINES; MALE; MICE; MOLECULAR DOCKING SIMULATION; NITROREDUCTASES; OXIDATION-REDUCTION; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TANDEM MASS SPECTROMETRY;

EID: 84952843612     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12155     Document Type: Article

References (38)

1. Tilg, H. & Kaser, A. Gut microbiome, obesity, and metabolic dysfunction. J. Clin. Invst. 121, 2126 (2011).
2. Koeth, R. A. et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19, 576-585 (2013).
3. Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57-63 (2011).
4. Tremaroli, V. & Backhed, F. Functional interactions between the gut microbiota and host metabolism. Nature 489, 242-249 (2012).
5. Kang, M. J. et al. The effect of gut microbiota on drug metabolism. Expert. Opin. Drug Met. 9, 1295-1308 (2013).
6. Sousa, T. et al. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int. J. Pharm. 363, 1-25 (2008).
7. Kong, W. et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 10, 1344-1351 (2004).
8. Zhang, H. et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 59, 285-292 (2010).
9. Yao, J., Kong, W. & Jiang, J. Learning from berberine: Treating chronic diseases through multiple targets. Sci. China Life Sci. doi: 10.1007/s11427-013-4568-z (2013).
10. Li, H. et al. Hepatocyte nuclear factor 1α plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J. Biol. Chem. 284, 28885-28895 (2009).
11. Lee, Y. S. et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55, 2256-2264 (2006).
12. Derosa, G., Maffioli, P. & Cicero, A. F. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert. Opin. Biol. Th. 12, 1113-1124 (2012).
13. Chen, W. et al. Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. Aaps. Pharmscitech. 12, 705-711 (2011).
14. Pan, G. Y., Wang, G. J., Liu, X. D., Fawcett, J. P. & Xie, Y. Y. The involvement of P-glycoprotein in berberine absorption. Pharmacol. Toxicol. 91, 193-197 (2002).
15. Tan, X. S. et al. Tissue distribution of berberine and its metabolites after oral administration in rats. PloS One 8, e77969 (2013).
16. Roldan, M. D., Perez-Reinado, E., Castillo, F. & Moreno-Vivian, C. Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol. Rev. 32, 474-500 (2008).
17. Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455-461 (2010).
18. Turner, N. et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex IA mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 57, 1414-1418 (2008).
19. Hasan, F., McCrodden, J., Kennedy, N. & Tipton, K. The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J. Neural Transm. Suppl. 26, 1-9 (1987).
20. Wang, Y. X. et al. Synthesis and biological evaluation of berberine analogues as novel up-regulators for both low-densitylipoprotein receptor and insulin receptor. Biorg. Med. Chem. Lett. 19, 6004-6008 (2009).
21. Wang, Y. X. et al. Synthesis and structure-activity relationship of berberine analogues in LDLR up-regulation and AMPK activation. Biorg. Med. Chem. 20, 6552-6558 (2012).
22. Li, Y. H. et al. Berberine Analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure- activity relationships, and cholesterol-lowering efficacy. J. Med. Chem. 52, 492-501 (2008).
23. Yang, P. et al. Synthesis and structure-activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators. Biorg. Med. Chem. Lett. 18, 4675-4677 (2008).
24. Bau, U. D. The antibacterial mechanism of berberis - I. The inhibition of respiration of Dysentery bacilli by berberis and berberine. Acta Microbiol. Sin. 4, 011 (1959).
25. Koder, R. L., Haynes, C. A., Rodgers, M. E., Rodgers, D. W. & Miller, A.-F. Flavin thermodynamics explain the oxygen insensitivity of enteric nitroreductases. Biochemistry 41, 14197-14205 (2002).
26. Zhang, C. H. et al. Structural modulation of gut microbiota in life-long calorie-restricted mice. Nat. Commun. 4, 2163 (2013).
27. Tang, W. W. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 368, 1575-1584 (2013).
28. Cani, P. D. & Delzenne, N. M. Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr. Opin. Pharmacol. 9, 737-743 (2009).
29. Musso, G., Gambino, R. & Cassader, M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr. Opin. Lipidol. 21, 76-83 (2010).
30. Yin, J., Ye, J. P. & Jia, W. P. Effects and mechanisms of berberine in diabetes treatment. Acta Pharm Sin B. 2, 327-334 (2012).
31. Xie, W. D., Gu, D. Y., Li, J. N., Cui, K. & Zhang, Y. O. Effects and action mechanisms of berberine and rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. PloS One 6, e24520 (2011).
32. Zhang, X. et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PloS One 7, e42529 (2012).
33. Fu, J. et al. Identification of metabolites of FR429, a potential antitumor ellagitannin, transformed by rat intestinal bacteria in vitro, based on liquid chromatography-ion trap-time of flight mass spectrometry analysis. J. Pharm. Biomed. Anal. 71, 162-167 (2012).
34. Ma, J. Y. et al. Excretion of berberine and its metabolites in oral administration in rats. J. Pharm. Sci. 102, 4181-4192 (2013).
35. National Committee for Clinical Laboratory Standards (NCCLS). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard 2nd edn M7-A4 (NCCLS, Villanova, Pennsylvania, USA, 1990).
36. Hubatsch, I., Ragnarsson, E. G. & Artursson, P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat. Protoc. 2, 2111-2119 (2007).
37. Funada, M., Aoo, N. & Wada, K. Rewarding effects of N-methyl-1-(4-Methoxyphenyl)-2-aminopropane (PMMA) in mice: role of modifications of dopamine system mediated through its monoamine oxidase inhibition. J. Addict Res. Ther. 5, 172-176 (2014).
38. Yang, H. Y. T. & Neff, N. H., The monoamine oxidases of brain: selectvie inhibitors with drugs and the consequences for the metabolism of the biogenic amines. J. Pharmacol. Exp. Ther. 189, 733-740 (1974).